Mutation Analysis in Chronic Myeloid Leukemia Patient in Chronic Phase on Imatinib Having Delayed Achievement of Milestones or Loss of Response
- 29 November 2016
- journal article
- research article
- Published by Springer Science and Business Media LLC in Indian Journal of Hematology and Blood Transfusion
- Vol. 33 (3), 316-320
- https://doi.org/10.1007/s12288-016-0755-y
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Report of patients with chronic myeloid leukemia Kidwai Memorial Institute of Oncology, Bangalore over 15 yearsIndian Journal of Medical and Paediatric Oncology, 2013
- Chronic myeloid leukemia data from IndiaIndian Journal of Medical and Paediatric Oncology, 2013
- Management of imatinib-resistant patients with chronic myeloid leukemiaTherapeutic Advances in Hematology, 2012
- Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experienceBlood, 2012
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNetBlood, 2011
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid LeukemiaClinical Cancer Research, 2006
- Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBlood, 2003
- CHRONIC MYELOGENOUS LEUKAEMIABritish Journal of Haematology, 2000
- Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemiaJCI Insight, 2000